Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome: The Headache of Nonevidence-Based Medicine for Ischemic Heart Disease?∗

JACC: Heart Failure

Volumn 6, Issue 2, 2018, Pages 168-171

  Cleland, John G F ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

aspirin; ischemic heart disease; lack of evidence; randomized trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG DEPENDENCE; EDITORIAL; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WELLBEING; ATRIAL FIBRILLATION; CARDIOLOGIST; HEADACHE; HEART MUSCLE ISCHEMIA;

ASPIRIN; ATRIAL FIBRILLATION; CARDIOLOGISTS; HEADACHE; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS;

EID: 85044868231     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.11.014     Document Type: Editorial

References (11)

1. Tolstoy K. Leo Tolstoy quotes. Available at: https://www.goodreads.com/quotes/106513-wrong-does-not-cease-to-be-wrong-because-the-majority. Accessed December 5, 2017.
2. Brainyquotes. Robert Burns' quotes. Available at: https://www.brainyquote.com/quotes/robert_burns_182938. Accessed December 5, 2017.
3. Cleland, J.G., Is aspirin “the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44 (2002), 275–292.
4. Cleland, J.G., Is aspirin useful in primary prevention?. Eur Heart J 34 (2013), 3412–3418.
5. Kolodgie, F.D., Gold, H.K., Burke, A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349 (2003), 2316–2325.
6. Cleland, J.G., Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!. Eur J Heart Fail 19 (2017), 1086–1088.
7. Madelaire, C., Gislason, G., Kristensen, S.L., et al. Low-dose aspirin in heart failure not complicated by atrial fibrillation: a nationwide propensity-matched study. J Am Coll Cardiol HF 6 (2018), 156–167.
8. Sondergaard, K.B., Weeke, P., Wissenberg, M., et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3 (2017), 100–107.
9. National Heart Failure Audit. April 2015–March 2016. Available at: http://www.ucl.ac.uk/nicor/audits/heartfailure/documents/annualreports/annual-report-2015-6-v8.pdf. Accessed December 27, 2017.
10. Zannad, F., Greenberg, B., Cleland, J.G., et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 17 (2015), 735–742.
11. Eikelboom, J.W., Connolly, S.J., Bosch, J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377 (2017), 1319–1330.